FDA grants priority review to pemigatinib for cholangiocarcinoma

The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer.Pemigatinib (Incyte), a selective fibroblast growth factor receptor (FGFR) inhibitor, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations. FGFR2 fusions or rearrangements occur in about 10% to 16% of patients with intrahepatic cholangiocarcinoma.The FDA based its decision, in part, on data from theRead More